Palomar Medical Expands Its Product Portfolio Through a Distribution Agreement with...

Palomar Medical Expands Its Product Portfolio Through a Distribution Agreement
with Astron Clinica

BURLINGTON, Mass., July 23 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of
light-based systems for cosmetic treatments, announced today that it has
entered into a Distribution Agreement with Astron Clinica, Ltd. to distribute
a range of aesthetic imaging products in the United States and Canada.
The agreement gives Palomar exclusive distribution rights to sell Beau
Visage(TM), a clinically proven skin imaging and consultation system, to
medical professionals. Palomar's customers can use Beau Visage(TM) during
initial client meetings to visualize and measure blood, pigment, and wrinkles
before recommending the most effective cosmetic treatments available using
Palomar's StarLux(TM) Laser and Pulsed Light System. Palomar's customers can
use Beau Visage during subsequent visits to show changes in their clients'
skin by tracking and measuring actual improvement in skin appearance.
Providing such quantifiable data on changes in skin health should greatly
improve client satisfaction.
Customers using Beau Visage in conjunction with Palomar products are able
to better tailor treatments to the specific needs of each client and then
demonstrate and quantify the before-and-after effect of Palomar treatments.
This should enable Palomar customers to sell more treatments, thereby
increasing revenue and decreasing time to return on investment in Palomar
aesthetic light based systems.
Also under the Distribution Agreement, Palomar will sell Astron Clinica's
Physiometrics(TM) photographic imaging system which captures a library of
images of the body. This new technology will allow for visual documentation of
the benefits that will be seen using the recently introduced Palomar
Aspire(TM) SlimLipo(TM) laser-assisted lipolysis system.
Commenting on this agreement Joseph P. Caruso, Chief Executive Officer of
Palomar, said, "Working with Astron Clinica enables Palomar to sell additional
products to its customers that help them increase revenues and improve client
satisfaction. Our customers will be able to use Astron Clinica products to
sell more aesthetic procedures, which are better tailored to the needs of each
specific client, and show clients their actual improvement."
Prof. Annie Brooking, CEO of Astron Clinica, said, "We are delighted with
this relationship with Palomar, the industry leader in light-based aesthetic
products. The products of Palomar and Astron Clinica are truly synergistic and
enable both companies to deliver a superior service to our customers."
About Palomar Medical Technologies, Inc.: Palomar is a leading researcher
and developer of light-based systems for cosmetic treatments. Palomar
pioneered the optical hair removal field, when, in 1997, it introduced the
first high-powered laser hair removal system. Since then, many of the major
advances in light-based hair removal have been based on Palomar technology. In
December 2006, Palomar became the first company to receive a 510(k)
over-the-counter (OTC) clearance from the United States Food and Drug
Administration (FDA) for a new, patented, home use, light-based hair removal
device. OTC clearance allows the product to be marketed and sold directly to
consumers without a prescription. There are now millions of light-based
cosmetic procedures performed around the world every year in physician
offices, clinics, spas and salons. Palomar is testing many new and exciting
applications to further advance the hair removal market and other cosmetic
applications. Palomar is focused on developing proprietary light-based
technology for introduction to the mass markets. Palomar has granted The
Procter & Gamble Company a non-exclusive License Agreement to certain patents,
technology and FDA documents related to the home-use, light-based hair removal
field for women. In addition, Palomar has an exclusive development and license
agreement with Johnson & Johnson Consumer Companies to develop and potentially
commercialize home-use, light-based devices for reducing or reshaping body fat
including cellulite, reducing the appearance of skin aging, and reducing or
preventing acne.
About Astron Clinica, Ltd.: Astron Clinica is a global skin imaging
company, based in Cambridge UK and with offices in New York and Brisbane.
Astron Clinica designs, develops and brings to market skin imaging products
that incorporate its proprietary skin imaging technology SIAscopy(TM).
SIAscopy(TM) uniquely enables medical, pharmaceutical, cosmetic and aesthetic
industry professionals to visualize up to 2mm beneath the surface of the skin
using both a proprietary hand held scanner and an off-the-shelf digital
camera. Awarded Frost & Sullivan's 2006 European Technology Innovation of the
Year Award, Astron Clinica's products use SIAscopy(TM) to allow the
measurement and non-invasive visualization of the major dermatological
constituents of skin -- blood, pigment and collagen -- in vivo for the first
time. SIAscopy(TM) is a technology that is trusted globally to help diagnose
skin conditions as severe as skin cancer. Astron Clinica's customers include
dermatologists, plastic surgeons, hospitals, GPs, beauty clinics and aesthetic
medicine practitioners.
This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based on the Company's current expectations, plans, intentions,
beliefs or predictions. These forward-looking statements are neither promises
nor guarantees, but involve risk and uncertainties that may individually or
mutually impact the matters herein, and cause actual results, events and
performance to differ materially from such forward-looking statements. These
risk factors include, but are not limited to, results of future operations,
technological difficulties in developing or introducing new products, the
results of future research, lack of product demand and market acceptance for
current and future products, the effect of economic conditions, challenges in
managing joint ventures and research with third parties and government
contracts, the impact of competitive products and pricing, governmental
regulations with respect to medical devices, including whether FDA clearance
will be obtained for future products and additional applications, the results
of litigation, including patent infringement lawsuits, difficulties in
collecting royalties, potential infringement of third-party intellectual
property rights, factors affecting the Company's future income and resulting
ability to utilize its NOLs, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on Form 10-K
for the year ended December 31, 2007 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
Contacts: Kayla Castle Prof. Annie Brooking
Investor Relations Manager Chief Executive Officer
Palomar Medical Technologies, Inc. Astron Clinica, Ltd.
781-993-2411 +44 1223 265000
kcastle@palomarmedical.com

SOURCE Palomar Medical Technologies, Inc.

Kayla Castle, Investor Relations Manager of Palomar Medical Technologies,
Inc., +1-781-993-2411, kcastle@palomarmedical.com; or Prof. Annie Brooking,
Chief Executive Officer of Astron Clinica, Ltd., +44-1223-265000